Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Coatue
BioCentury | Oct 5, 2023
Regulation
Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma
Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
BioCentury | Jun 4, 2022
Regulation
June 3 Quick Takes: myocarditis risk weighs on Novavax stock
Plus venture money for Vizgen, Watchmaker, Latch Bio, Endpoint Health
BioCentury | Apr 21, 2022
Deals
April 21 Quick Takes: Reify’s big round to support clinical trial diversity
Plus Terran gains rights to two late-stage candidates from Sanofi, and updates from Ampio, Nephris, Jacobus and more
BioCentury | Oct 27, 2021
Product Development
Oct. 26 Quick Takes: CD8 Treg modulating play Mozart debuts with $55M
Angion, Cortexyme post Phase III misses, plus DNA Script, Novartis, Quanta, Exciva and more
BioCentury | Aug 12, 2021
Finance
Aug. 11 Quick Takes: Digital therapeutics play Mahana secures $61M series B
Plus: Reify raises $220M C round for decentralized trial platform, and updates from Biogen, Pfizer-Fera, Astellas and more
BioCentury | Jul 14, 2021
Finance
July 14 Quick Takes: Patient Square Capital leads Kriya’s $100M B round; plus Entos, Ribon and more
Patient Square Capital led a $100 million series B round for Kriya Therapeutics Inc. to advance a pipeline of gene therapies for patients with prevalent and severe chronic diseases. New investors
BioCentury | May 12, 2021
Deals
May 11 Quick Takes: $830M for tumor profiler Caris; plus Nuvalent’s $135M series B, Ginkgo’s $2.5B SPAC and updates from Adaptive, LianBio-Nanobiotix, Phico, Laevoroc
Sixth Street has made its third investment in molecular profiling company Caris Life Sciences Inc., leading a $830 million round at a postmoney valuation of $7.8 billion. The investment comes less
BioCentury | Oct 27, 2020
Finance
Tumor profiling play Caris to grow biopharma partnerships with $310M round
With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships. The round, which includes Caris Life
Items per page:
1 - 8 of 8